The article looks to the backlash surrounding the Solvadi drug, produced by Gilead Sciences, as the cause for an 85% increase in mentions from last year.
BDO USA partner Ryan Starkes commented on the large uptick saying, “This caught our eye. There’s a real challenge that healthcare providers have made (over the costs of drugs)…more so than before, this is a concern.”
When annoucing the report, BDO USA stated, “Recent headlines around Gilead’s launch of Solvaldi…shed light on the delicate balance between charging a ‘fair’ price for the value provided by a drug and the ability of healthcare systems to reimburse the costs.”
To read the article in full, click here.
